PepEvolutionBPC-157 Dosage: What the Research Shows
BPC-157 · Body Protection Compound-157
Status & framing. BPC-157 is a research peptide. It is NOT an FDA-approved drug and has no established human therapeutic dose. Most published data is preclinical (animal). Figures below are doses used in studies, cited, not a recommendation.
What the research shows
Most BPC-157 dosing figures circulating online are extrapolated from rodent studies, where doses are typically reported per kilogram of body weight (µg/kg). Human clinical data is limited. The most commonly cited human-oriented figures (roughly 200-500 mcg per injection, once or twice daily) are practitioner conventions derived by scaling animal data, not values validated in a registered human trial.
Doses used in studies
Each row is a dose as reported in the cited source, not a recommendation. Superscripts link to sources below.
| Context | Dose studied | Route / frequency |
|---|---|---|
| Soft-tissue / tendon-ligament repair (preclinical) | ~10 µg/kg body weight[1][2]⚠ Animal data. Per-kg rodent dosing does not translate directly to a fixed human dose. | Intraperitoneal or intramuscular, in rodents |
| Gastrointestinal / gut-lining models (preclinical) | ~10 µg/kg body weight[1]⚠ Animal data. | Oral or intraperitoneal, in rodents |
| Practitioner-reported human conventions | ≈200-500 mcg per injection, 1-2× daily[1]⚠ Not from a registered human trial, a scaled convention, presented for reference only. | Subcutaneous, near or systemic to the target area |
Reconstitution & example math
A 5 mg vial reconstituted with 2 mL of bacteriostatic water yields 2.5 mg/mL (2,500 mcg/mL). A 250 mcg dose is then 0.1 mL, 10 units on a U-100 insulin syringe. That vial provides 20 doses of 250 mcg.
BPC-157 is generally reconstituted with bacteriostatic water and refrigerated after mixing. Add water slowly down the vial wall; do not shake vigorously.
Route, half-life & timing
Safety & side-effect notes from the literature
- BPC-157 has one of the cleaner reported safety profiles among research peptides, with low acute toxicity in animal studies.[1]
- Human long-term safety data is limited. It is not FDA-approved and was nominated for review under FDA compounding rules.[3]
- Because it promotes angiogenesis in models, its effect in the presence of active malignancy is not established, a reason caution is advised.[2]
Frequently asked
What dose of BPC-157 is used in research?+
Preclinical (animal) studies most often report roughly 10 µg per kg of body weight. Practitioner conventions scaled from that data commonly cite about 200-500 mcg per injection, once or twice daily. There is no FDA-approved human dose.
How do you reconstitute BPC-157?+
A common approach is 2 mL of bacteriostatic water into a 5 mg vial, giving 2.5 mg/mL. A 250 mcg dose is then 0.1 mL, or 10 units on a U-100 insulin syringe. Refrigerate after mixing.
Is BPC-157 FDA-approved?+
No. BPC-157 is a research peptide with no FDA-approved human dose. The figures on this page are doses used in published studies, presented for education only.
Get the full BPC-157 protocol
PepEvolution Pro turns these research ranges into a personalized schedule, a full BPC-157 protocol with a week-by-week plan, sourcing shortlist, and COA-checked vendors. Educational, cited, and built on the same methodology.
See what's in Pro →Email me the BPC-157 protocol
Get this BPC-157 dosing summary plus related reconstitution and sourcing guides. Research/educational only.
Sources & Citations
Primary sources only. Doses are stated as reported, see methodology.
Related
Educational only, not medical advice. Doses on this page are figures used in published research or clinical labeling, presented for education. They are not a prescription or a recommendation to self-administer. Consult a licensed healthcare provider before using any compound.